Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ATIS is on the move! -- Ignore unavailable to you. Want to Upgrade?

To: g.w. barnard who wrote (1786)	4/12/1999 9:43:00 PM
From: John J. Frawley	Read Replies (1) \| Respond to of 2205

CNBC Power Lunch Interview today - Was able to catch parts. Short segment - 5+ minutes with Gail. Split Screen Format - Interview on right half, facts about co on left. Reason for segment - Viewer requests, based on "Friday shows (?)." Gail's presentation - well prepared, looked like she wanted to get out the company's basic story. This was the first time I'd ever seen her. She seemed "CEO Impressive." Major revelation (for me) - When asked when ATIS would start turning a profit, she replied that it would be soon and that a number of products (other than the main ones we know of), are in the pipeline. She used the example of "injectable collegen." I have no idea what this is, sounds like a cosmetic item. Additionally, She reiterated that ATIS' plan is to develop and manufacturer. The products have been developed and the manufacturing facilities have been build and have met approval. I remember her mentioning approval of the facilities, but not the FDA specifically. Facts about company - the screen rolled through several items: Sales growth of 40%, Trancyte, sales in Europe and Canada, and many others John F.